MEDRAD, BATTELLE WIN MEDICAL DESIGN EXCELLENCE AWARD FOR MEDRAD XDS™ EXTRAVASATION DETECTOR

Medical Design Excellence Awards is the Premier Award Program for  Medical Technology

 

Columbus, OH—MEDRAD, INC. and Battelle, the world's largest non-profit independent research and development organization, today announced the winning of a Medical Design Excellence Award (MDEA) for the MEDRAD XDS™  Extravasation Detector, a technology that enhances the safety of contrast media injection through early detection of extravasations.  Extravasation is leakage of fluid, including contrast media, drugs, or solutions, from a vein into the surrounding tissue during intravenous administration.

 

The MDEA competition is a prestigious program recognizing medical product excellence and the achievements of medical product manufacturers (and the people who are responsible for groundbreaking innovations that are changing the face of healthcare).  An impartial, multi-disciplinary panel of jurors with expertise in biomedical engineering, human factors, industrial design, medicine, and diagnostics reviewed the entries and selected the winners.

 

“We thank MD&DI for this prestigious MDEA that recognizes our XDS Extravasation Detector technology, the investment of many resources for research and development, and the inherent risk of developing medical devices; the MDEA validates that the investment and risk were worth it,” said Cliff Kress, senior vice president, MEDRAD CT Business Unit.  “We’re also proud that we succeeded where others have not in developing an extravasation technology with a major impact on safety and a minor impact on workflow.”

 

Battelle worked closely with MEDRAD to develop the technology from exploration through product development.  MEDRAD and Battelle jointly invented the electrical permittivity technology that enables XDS™ and developed the commercial product.

 

XDS™ continuously monitors the tissue immediately surrounding and directly beneath the injection site for changes in relative permittivity signaling fluid accumulation.

 

“Battelle is pleased that our long-standing relationship with MEDRAD has yielded this breakthrough product,” said Barbara Kunz, President, Battelle Health and Life Sciences Global Business.  “Together, we have made a difference in patient safety and have improved the quality of care for patients undergoing imaging studies.”

 

MEDRAD and Battelle will accept the award at a ceremony on June 4, 2008, at the Medical Design & Manufacturing (MD&M) East 2008 Conference and Exposition in New York City.  Additionally, the MEDRAD XDS™ Extravasation Detector will appear with the other MDEA winners in the April 7 issue of Medical Device & Diagnostic Industry (MD&DI).

 

About Battelle

 

Battelle’s Global Health and Life Sciences business delivers a comprehensive set of R&D services to solve complex challenges for government health agencies and medical device, biotechnology, and pharmaceutical firms.  Including its national laboratories, Battelle oversees over $200 million annually in health and life sciences-research contributing to advances in medical devices, pharmaceuticals, public health, and next-generation diagnostics and therapeutics.

 

Battelle is the world's largest non-profit independent research and development organization, overseeing 20,000 employees in more than 130 locations worldwide, including five national laboratories Battelle manages or co-manages for the U.S. Department of Energy.  Headquartered in Columbus, Ohio, Battelle conducts $4 billion in R&D annually through contract research, laboratory management, and technology commercialization.  As a non-profit charitable trust with an eye toward the future, Battelle actively supports and promotes science and math education.

 

For more information, contact Media Relations Manager Katy Delaney at

(410) 306-8638.